This presentation provides an in-depth review of the Texas Compassionate Use Program (T-CUP) and its evolving role in clinical practice. Topics include legislative developments, qualifying conditions, and recent regulatory changes impacting prescribing and formulation options. The session will examine evidence-based applications of cannabidiol (CBD) and tetrahydrocannabinol (THC) in neurological and systemic disorders, including epilepsy, autism spectrum disorder, multiple sclerosis, PTSD, and chronic pain. Attendees will also explore dosing strategies, delivery methods, and the pharmacologic considerations of cannabinoids and terpenes, alongside institutional policy challenges and future directions for therapeutic cannabis in Texas.